Clinical Trials Sponsored by Genta Incorporated

Total 1287 results

Genta Incorporated

Unknown

A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors

Solid Tumor

United States
Genta Incorporated

Completed

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

Solid Tumors

United States
Genta Incorporated

Completed

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Solid Tumors

United States
Genta Incorporated

Unknown

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction

United States, Korea, Republic of
Genta Incorporated

Unknown

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Gastric Carcinoma

Korea, Republic of
Genta Incorporated

Completed

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Advanced Melanoma
Genta Incorporated

Unknown

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Melanoma

United States
Genta Incorporated

Completed

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | CLL

United States
Genta Incorporated

Unknown

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Breast Neoplasm

United States
Genta Incorporated

Unknown

Study of Tesetaxel in Japanese Patients With Solid Tumors

Advanced Solid Tumors

Japan
Genta Incorporated

Completed

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

Normal Renal Function | Mildly Impaired Renal Function | Moderately Impaired Renal Function

United States
Genta Incorporated

Unknown

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Melanoma

United States
Genta Incorporated

Completed

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Genta Incorporated

Completed

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (AGENDA)

Melanoma

United States, France, United Kingdom, Spain, Switzerland, Australia, Canada, Germany, Poland, Italy, Austria, Czech Republic
Genta Incorporated

Withdrawn

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Lymphocytic Leukemia
Genta Incorporated

Completed

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Tumors

United States
Genta Incorporated

Unknown

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer (TESEGAST)

Gastric Carcinoma

Taiwan, United States, Germany
Genta Incorporated

Unknown

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Prostate Cancer

United States
Genta Incorporated

Unknown

Tesetaxel for Previously Treated Patients With Bladder Cancer

Carcinoma, Transitional Cell

United States, Italy
Genta Incorporated

Unknown

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Non-resectable Breast Cancer

United States
Genta Incorporated

Terminated

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Advanced Melanoma and Normal or Impaired | Hepatic Function
Genta Incorporated

Completed

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Low-Grade Lymphoma | Intermediate-Grade Lymphoma

United States
Loyola University
Genta Incorporated

Withdrawn

Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States
M.D. Anderson Cancer Center
Genta Incorporated

Completed

Phase II Study of Tesetaxel in Metastatic Melanoma

Cancer | Advanced Melanoma

United States
M.D. Anderson Cancer Center
Genta Incorporated

Terminated

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Melanoma

United States
Genta Incorporated
National Cancer Institute (NCI)

Unknown

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada, Russian Federation
Genta Incorporated

Completed

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Genta Incorporated

Completed

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Genta Incorporated

Completed

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Melanoma (Skin)

United States
Genta Incorporated

Completed

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Leukemia

United States
University of Nebraska
National Cancer Institute (NCI); Genta Incorporated

Terminated

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
PENTA Foundation

Completed

Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children (PENTA 13)

HIV Infection

United Kingdom
PENTA Foundation

Active, not recruiting

Early Anti-Retroviral Treatment in HIV- Infected Children

HIV Infections

South Africa, Mali, Mozambique
PENTA Foundation

Completed

PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months (PENTA15)

HIV Infection

France, Germany, Italy, Spain, United Kingdom
Kenta Biotech Ltd

Completed

Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa

Pneumonia | Ventilator Associated Pneumonia

Switzerland
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Inguinal Hernia Study Using Biodesign IHM

Inguinal Hernia

United States
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery

Obesity | Hernia

United States
Cook Research Incorporated

Recruiting

Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered

Esophageal Diseases

Germany, Spain, United Kingdom
Cook Research Incorporated

Recruiting

Zenith® Fenestrated+ Clinical Study

Aortic Aneurysm, Abdominal | Juxtarenal Aortic Aneurysm | Extent IV Thoracoabdominal | Pararenal Aneurysm

United States
Cook Research Incorporated

Recruiting

Biodesign® Otologic Repair Graft

Tympanic Membrane Perforation | Eardrum Perforation

United States
Cook Research Incorporated

Completed

Comparing a Direct Versus an Indirect Approach to Measuring the Portalsytemic Pressure Gradients

Liver Cirrhosis

Belgium, Spain, Netherlands
Cook Research Incorporated

Completed

Zenith® p-Branch® and Zenith® Fenestrated AAA Endovascular Graft Clinical Study (FENP)

Aortic Aneurysm, Abdominal

United States
Cook Research Incorporated

Completed

Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Liver Diseases | Liver Cirrhosis | Hypertension, Portal

United States, Australia, Hong Kong
Cook Research Incorporated

Completed

Zilver® PTX® V Clinical Study

Peripheral Arterial Disease

United States
Cook Research Incorporated

Completed

Zenith TX2® Post-market Approval Study (TX2 2PAS)

Descending Thoracic Aortic Aneurysm

United States, Canada
Cook Research Incorporated

Completed

Zenith® Dissection Clinical Trial

Aortic Dissection

United States, Japan
Cook Research Incorporated

Terminated

HemaTrate™ in the Treatment of Critical Limb Ischemia

Ischemia | Critical Limb Ischemia

United Kingdom
Cook Research Incorporated

Completed

Cook Enforcer Post-Market Study

End-Stage Renal Disease

United States
Cook Group Incorporated
Cook Biotech Incorporated

Terminated

Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft (SurgiSIS AFP)

Crohn's Disease | Anal Fistula

United States
Insmed Incorporated

Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark

Clinical Trials Sponsored by Genta Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations